Actively Recruiting
Serial MRI Scans During Radiation Therapy
Led by Dana-Farber Cancer Institute · Updated on 2025-08-26
149
Participants Needed
2
Research Sites
550 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase 1 study to determine the feasibility and utility of using serial magnetic resonance imaging (MRI) to assess treatment response during and after radiation therapy (standard of care cancer treatment) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma. The research study procedures include three MRI scans (one before, one during, and one after standard of care cancer radiation therapy) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma. The research study procedures include: * Screening for eligibility * Three MRI scans
CONDITIONS
Official Title
Serial MRI Scans During Radiation Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have a confirmed malignancy requiring radiation therapy.
- Participants must be 18 years or older except where otherwise specified in subprotocol.
- ECOG performance status 2 or less (Karnofsky 60% or higher).
- Ability to understand and willingness to sign a written informed consent document.
- Any additional criteria listed in the specific disease site subprotocol.
- Esophageal cohort: Candidates for neoadjuvant chemoradiation followed by esophagectomy with baseline or scheduled endoscopic ultrasound.
- Glioblastoma cohort: Newly diagnosed intracranial glioblastoma or gliosarcoma patients undergoing radiation therapy.
- Prostate cohort: Localized prostate cancer patients planning androgen deprivation therapy and radiation therapy.
- Vulvar cohort: Biopsy-proven locally advanced vulvar cancer patients planned for definitive radiotherapy.
- Pediatric glioma cohort: Patients 18 or under, or 18-30 if tumor biology matches pediatric high-grade glioma; histologically confirmed high-grade glioma undergoing radiation therapy; only biopsy-confirmed high grade DIPG eligible.
- Ability or willingness of parent or legal representative to sign informed consent for pediatric patients.
You will not qualify if you...
- Disease-specific exclusion criteria will be detailed in subprotocols.
- History of allergic reaction to gadolinium-based IV contrast if MRI with contrast is required.
- Inability to undergo MRI scanning.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Brigham and Women Hospital
Boston, Massachusetts, United States, 02115
Actively Recruiting
2
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
Research Team
J
Jonathan Leeman, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
OTHER
Number of Arms
8
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here